MedPath

A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1

Phase 2
Completed
Conditions
Diabetes Mellitus
Interventions
Registration Number
NCT02221323
Lead Sponsor
Profil Institut für Stoffwechselforschung GmbH
Brief Summary

The aim of this trial is to compare the pharmacokinetics and pharmacodynamics of insulin lispro injection into either lipohypertrophic lesions or normal tissue, utilizing both state-of-the-art euglycaemic clamp and mixed meal tolerance testing. The magnitude of insulin efficacy after injection into these different areas is still unclear. The results from this study may expand the knowledge on the severity of this issue and may provide evidence for future treatment recommendations regarding injection sites for insulin administration.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
18
Inclusion Criteria
  • AUCINS.0-4h and AUCGIR.0-4h during treatment period 1
Exclusion Criteria
  • AUCINS.0-4h and AUCBG.0-4h during treatment period 2, intra-subject variability of AUCINS.0-4h and AUCGIR.0-4h during treatment period 1

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Insulin lisproInsulin LISPRO-
Primary Outcome Measures
NameTimeMethod
AUCINS.0-4h and AUCGIR.0-4hup to 4 hours

Compare the pharmacokinetic and pharmacodynamic effects of insulin lispro during the first 4 hours after s.c.

administration into either lipohypertrophic or normal adipose tissue during a euglycaemic clamp examination.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Profil Institut für Stoffwechselforschung GmbH

🇩🇪

Neuss, NRW, Germany

© Copyright 2025. All Rights Reserved by MedPath